Home/Filings/4/0001209191-20-052334
4//SEC Filing

ORONSKY ARNOLD L 4

Accession 0001209191-20-052334

CIK 0001699382other

Filed

Sep 28, 8:00 PM ET

Accepted

Sep 29, 4:33 PM ET

Size

21.7 KB

Accession

0001209191-20-052334

Insider Transaction Report

Form 4
Period: 2020-09-25
ORONSKY ARNOLD L
Director10% Owner
Transactions
  • Conversion

    Common Stock

    2020-09-29+1,620,1011,675,101 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock

    2020-09-291,040,6540 total(indirect: See footnote)
    Common Stock (1,040,654 underlying)
  • Conversion

    Common Stock

    2020-09-29+3,488,3985,163,499 total(indirect: See footnote)
  • Conversion

    Series Seed Preferred Stock

    2020-09-291,620,1010 total(indirect: See footnote)
    Common Stock (1,620,101 underlying)
  • Purchase

    Common Stock

    2020-09-25$18.00/sh+55,000$990,00055,000 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-09-29+1,040,6546,204,153 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-09-29+265,2036,469,356 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2020-09-293,488,3980 total(indirect: See footnote)
    Common Stock (3,488,398 underlying)
  • Conversion

    Series C Preferred Stock

    2020-09-29265,2030 total(indirect: See footnote)
    Common Stock (265,203 underlying)
Footnotes (2)
  • [F1]The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
  • [F2]The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

Issuer

PMV Pharmaceuticals, Inc.

CIK 0001699382

Entity typeother

Related Parties

1
  • filerCIK 0001207833

Filing Metadata

Form type
4
Filed
Sep 28, 8:00 PM ET
Accepted
Sep 29, 4:33 PM ET
Size
21.7 KB